Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

OBAI vs LNAI: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LNAI Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 6–2 Matrix Metrics)

LNAI Overall Winner 6-Pillar Tally: OBAI 1 – 3 LNAI (2 Tie) Matrix Metrics: OBAI 2 – 6 LNAI

As of Nov 16, 2026, Lunai Bioworks Inc. (LNAI) is the stronger overall head-to-head candidate over OBAI (OBAI) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). OBAI carries a Unified Composite Score of 42.0/100 (HOLD) at $1.60 (N/M Forward P/E, N/A operating margin), whereas LNAI carries 44.1/100 (HOLD) at $0.16 (N/M Forward P/E, -6888.6% operating margin).

  • Technical & Structure Timing Caution: OBAI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 52.7); meanwhile LNAI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 13.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About OBAI vs LNAI
OBAI US Equity
OBAI
Institutional Equity
$1.60
-3.03% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 5.81β · 117% Vol
Unified Composite Score
42.0 / 100 HOLD
Tech 30.0 Fund 35.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (184.2% over 20 days), RSI 53
RSI-14: 52.7 · SMA20: $1.96 · SMA50: $0.98
LNAI NASDAQ Head-to-Head Winner
Lunai Bioworks Inc. Common Stock
Pharmaceutical Preparations
$0.16
-30.2% 1D
Market Cap $1.2M
TTM Revenue $51,992
Forward P/E N/M
Beta / 30D Vol 3.92β · 186% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 45.0 Fund 43.0 Flow 43.0 Mom 40.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -27.8%), weak momentum, RSI 13
RSI-14: 13.3 · SMA20: $0.74 · SMA50: $1.61

6-Pillar Scorecard Institutional Category Breakdown (OBAI 1 – 3 LNAI)

Columns: Metric · OBAI · LNAI
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale LNAI
Revenue Growth (YoY) N/A +0.0%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $51,992
Market Cap N/A $1.2M
3. Profitability & Quality LNAI
Gross Margin N/A 100.0%
Operating Margin N/A -6888.6%
Net Profit Margin N/A 0.0%
Return on Equity (ROE) N/A -325.5%
4. Balance Sheet & Cash Flow LNAI
Cash Generation (TTM) N/A -$7.8M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $1.7M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning OBAI
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 0.1% (50th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: OBAI (2) vs LNAI (6)
Institutional Metric OBAI LNAI Criterion Row Edge
Market Capitalization
Scale
N/A $1.2M Larger Scale LNAI
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A +0.0% Higher Growth LNAI
Operating Margin (TTM)
Profitability
N/A -6888.6% Higher Margin LNAI
Net Profit Margin
Profitability
N/A 0.0% Higher Margin LNAI
Return on Equity (ROE)
Capital Efficiency
N/A -325.5% Higher ROE LNAI
52-Week Range Position
Momentum
4% ($0–$38) 0% ($0–$5) Stronger Trend OBAI
Beta / 30D Volatility
Risk Regime
5.81β · 117% Vol 3.92β · 186% Vol Lower Realized Risk OBAI
Unified Institutional Score
Composite Signal
42.0 / 100 (HOLD) 44.1 / 100 (HOLD) Higher Composite LNAI
Trailing 12M Revenue (USD)
Operating Scale
N/A $51,992 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$7.8M EBITDA ($1.7M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon OBAI +779.26 pp
OBAI: +690.47% · LNAI: -88.79%
3M Horizon OBAI +386.07 pp
OBAI: +294.56% · LNAI: -91.51%
6M Horizon OBAI +325.28 pp
OBAI: +275.22% · LNAI: -50.06%
1Y Horizon LNAI +17.73 pp
OBAI: -93.67% · LNAI: -75.94%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on OBAI vs LNAI. Trailing 12-month operating profitability (OBAI N/A vs LNAI -6888.6%) and valuation multiples (OBAI N/M vs LNAI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

OBAI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
LNAI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$51,992
Gross Margin100.0%
Op. Margin-6888.6%
ROE / Fwd P/E-325.5% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
OBAI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact OBAI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LNAI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.1%
IV Percentile 50th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact LNAI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
OBAI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LNAI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.2M market capitalization and -6888.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ OBAI vs LNAI Key Questions & Quantitative Answers

As of Nov 16, 2026, Lunai Bioworks Inc. (LNAI) is the stronger overall head-to-head candidate over OBAI (OBAI) in the Tradestie Institutional Equity Comparison Engine, winning 6–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). OBAI carries a Unified Composite Score of 42.0/100 (HOLD) at $1.60 (N/M Forward P/E, N/A operating margin), whereas LNAI carries 44.1/100 (HOLD) at $0.16 (N/M Forward P/E, -6888.6% operating margin). Technical & Structure Timing Caution: OBAI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 52.7); meanwhile LNAI is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 13.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LNAI leads the Growth & Scale pillar: OBAI posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with LNAI at +0.0% YoY revenue growth and +0.0% YoY earnings growth on $51,992 TTM revenue (100.0% gross margin, -6888.6% operating margin). On trailing 12-month operating scale, OBAI generates N/A in USD-normalized revenue versus $51,992 for LNAI. In operating R&D and SG&A reinvestment, OBAI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for LNAI.

OBAI and LNAI trade at balanced relative valuation multiples. OBAI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas LNAI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against OBAI (N/A ROE) versus LNAI (-325.5% ROE) capital efficiency.

In options market volatility and institutional positioning, OBAI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (5.81β · 117% Vol realized risk). By comparison, LNAI carries 0.1% implied volatility (50th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (3.92β · 186% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.